<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>Contagion Live articles</title><description>Contagion Live articles</description><link>https://www.contagionlive.com/news</link><category>Contagion Live articles</category><copyright>© 2026 MJH Life Sciences™ and Contagion Live. All rights reserved.</copyright><lastBuildDate>Wed, 18 Nov 2026 15:53:42 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.contagionlive.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>Contagion Live articles</title><width>144</width><height>47</height><link>https://www.contagionlive.com/news</link><url>https://www.contagionlive.com/logo.webp</url></image><item><title>&lt;![CDATA[FAQ: What Does it Mean for the US to Lose its Measles Status? ]]&gt;</title><link>https://www.contagionlive.com/view/faq-what-does-it-mean-for-the-us-to-lose-its-measles-status-</link><guid isPermaLink="true">https://www.contagionlive.com/view/faq-what-does-it-mean-for-the-us-to-lose-its-measles-status-</guid><description>&lt;![CDATA[Here is what clinicians and the public need to know about PAHO’s decision to withdraw US measles elimination status and the outbreaks behind it.]]&gt;</description><pubDate>Tue, 17 Nov 2026 17:12:23 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[It&apos;s Official: US Loses Measles Elimination Status]]&gt;</title><link>https://www.contagionlive.com/view/it-s-official-us-loses-measles-elimination-status</link><guid isPermaLink="true">https://www.contagionlive.com/view/it-s-official-us-loses-measles-elimination-status</guid><description>&lt;![CDATA[PAHO formally withdraws US measles elimination status after its commission finds endemic transmission reestablished.]]&gt;</description><pubDate>Tue, 17 Nov 2026 16:44:55 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[WHO Reports 2 MERS Cases in Qatar, First Since 2022]]&gt;</title><link>https://www.contagionlive.com/view/who-reports-2-mers-cases-in-qatar-first-since-2022</link><guid isPermaLink="true">https://www.contagionlive.com/view/who-reports-2-mers-cases-in-qatar-first-since-2022</guid><description>&lt;![CDATA[The World Health Organization (WHO) confirmed 2 sporadic, camel-linked MERS-CoV infections with both patients recovered and no secondary transmission among 99 traced contacts.]]&gt;</description><pubDate>Tue, 17 Nov 2026 15:02:57 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[EMA Backs 3-Month Dapivirine Ring for HIV Prevention in Women]]&gt;</title><link>https://www.contagionlive.com/view/ema-backs-3-month-dapivirine-ring-hiv-prevention-women</link><guid isPermaLink="true">https://www.contagionlive.com/view/ema-backs-3-month-dapivirine-ring-hiv-prevention-women</guid><description>&lt;![CDATA[The EMA issued a positive opinion for a 3-month dapivirine vaginal ring for HIV prevention in women and girls aged 16 and older, cutting annual product costs by nearly 60%.]]&gt;</description><pubDate>Mon, 16 Nov 2026 22:07:14 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Cefazolin Possibly Superior, Probably Safer than Cloxacillin for MSSA Bacteremia]]&gt;</title><link>https://www.contagionlive.com/view/cefazolin-possibly-superior-probably-safer-than-cloxacillin-for-mssa-bacteremia</link><guid isPermaLink="true">https://www.contagionlive.com/view/cefazolin-possibly-superior-probably-safer-than-cloxacillin-for-mssa-bacteremia</guid><description>&lt;![CDATA[Cefazolin evidenced non-inferiority and probable superiority, as well as greater safety compared to antistaphylococcal penicillins for methicillin-susceptible S aureus bacteremia, in meta-analysis of direct comparison trials.]]&gt;</description><pubDate>Mon, 16 Nov 2026 18:16:10 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[CHMP Recommends Dolutegravir, Dolutegravir/Lamivudine for Children With HIV]]&gt;</title><link>https://www.contagionlive.com/view/chmp-recommends-dolutegravir-dolutegravir-lamivudine-for-children-with-hiv</link><guid isPermaLink="true">https://www.contagionlive.com/view/chmp-recommends-dolutegravir-dolutegravir-lamivudine-for-children-with-hiv</guid><description>&lt;![CDATA[The CHMP has recommended expanding dolutegravir to term newborns weighing at least 2 kg and dolutegravir/lamivudine to children as young as 3 months, and European Commission decisions are expected in Q1 2027.]]&gt;</description><pubDate>Mon, 16 Nov 2026 15:08:31 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Ebola Outbreak Reaches 11,145 Cases, 5437 Deaths]]&gt;</title><link>https://www.contagionlive.com/view/ebola-outbreak-reaches-11-145-cases-5437-deaths</link><guid isPermaLink="true">https://www.contagionlive.com/view/ebola-outbreak-reaches-11-145-cases-5437-deaths</guid><description>&lt;![CDATA[The Bundibugyo Ebola outbreak in the Democratic Republic of Congo has reached 11,145 confirmed cases and 5437 deaths, now the second-largest Ebola outbreak on record.]]&gt;</description><pubDate>Sun, 15 Nov 2026 12:18:16 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Reports Say US Loses Measles Elimination Status After 26 Years]]&gt;</title><link>https://www.contagionlive.com/view/reports-say-us-loses-measles-elimination-status-after-26-years</link><guid isPermaLink="true">https://www.contagionlive.com/view/reports-say-us-loses-measles-elimination-status-after-26-years</guid><description>&lt;![CDATA[The Pan American Health Organization has reportedly revoked the US measles elimination status after more than 12 months of continuous transmission, as 2026 cases top 5,400, states report 10 deaths, and kindergarten MMR coverage has fallen to 92.4%.]]&gt;</description><pubDate>Sat, 14 Nov 2026 15:16:02 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Peggy Lillis Foundation Expands C diff Campaign to Pediatric Population, Survivors]]&gt;</title><link>https://www.contagionlive.com/view/peggy-lillis-foundation-expands-c-diff-campaign-to-pediatric-population-survivors</link><guid isPermaLink="true">https://www.contagionlive.com/view/peggy-lillis-foundation-expands-c-diff-campaign-to-pediatric-population-survivors</guid><description>&lt;![CDATA[The Peggy Lillis Foundation&apos;s CEO and Co-founder Christian Lillis discusses the organization&apos;s initiatives for C diff month, and offers a glimpse of the upcoming Scientific Symposium they are hosting next week. ]]&gt;</description><pubDate>Sat, 14 Nov 2026 13:12:39 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Stewardship and Empiric Therapy in AMR Gram-Negative Infections]]&gt;</title><link>https://www.contagionlive.com/view/stewardship-and-empiric-therapy-in-amr-gram-negative-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/stewardship-and-empiric-therapy-in-amr-gram-negative-infections</guid><description>&lt;![CDATA[Effective stewardship of novel gram-negative agents pairs restriction with deliberate promotion of timely empiric use in high-risk patients, keeping optimized outcomes, rather than limitation, as the central goal.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:57:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Microbiology Lab Readiness and Education in AMR Care]]&gt;</title><link>https://www.contagionlive.com/view/microbiology-lab-readiness-and-education-in-amr-care</link><guid isPermaLink="true">https://www.contagionlive.com/view/microbiology-lab-readiness-and-education-in-amr-care</guid><description>&lt;![CDATA[Early collaboration with microbiology laboratories, reflex testing algorithms, and mechanism-based teaching help ensure that new antimicrobials reach the right patients and that resistance results are interpreted correctly.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:56:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Building the Formulary Case for Novel AMR Antibiotics]]&gt;</title><link>https://www.contagionlive.com/view/building-the-formulary-case-for-novel-amr-antibiotics</link><guid isPermaLink="true">https://www.contagionlive.com/view/building-the-formulary-case-for-novel-amr-antibiotics</guid><description>&lt;![CDATA[Securing formulary access to novel gram-negative agents depends on local epidemiology, outcome data, and electronic order safeguards, communicated clearly to committees that often lack infectious diseases expertise.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:55:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Weighing Cefiderocol and Combination Therapy for Stenotrophomonas]]&gt;</title><link>https://www.contagionlive.com/view/weighing-cefiderocol-and-combination-therapy-for-stenotrophomonas</link><guid isPermaLink="true">https://www.contagionlive.com/view/weighing-cefiderocol-and-combination-therapy-for-stenotrophomonas</guid><description>&lt;![CDATA[Cefiderocol&apos;s first-line recommendation for Stenotrophomonas maltophilia rests on compelling preclinical data that historic agents lack, but sparse clinical evidence supports initial combination therapy in critically ill patients.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:54:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter]]&gt;</title><link>https://www.contagionlive.com/view/sulbactam-durlobactam-for-carbapenem-resistant-acinetobacter</link><guid isPermaLink="true">https://www.contagionlive.com/view/sulbactam-durlobactam-for-carbapenem-resistant-acinetobacter</guid><description>&lt;![CDATA[After distinguishing true infection from colonization, the updated guidance positions sulbactam-durlobactam combined with a carbapenem as the clearly preferred regimen for carbapenem-resistant Acinetobacter baumannii.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:53:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Treating Difficult-to-Treat Resistant Pseudomonas aeruginosa]]&gt;</title><link>https://www.contagionlive.com/view/treating-difficult-to-treat-resistant-pseudomonas-aeruginosa</link><guid isPermaLink="true">https://www.contagionlive.com/view/treating-difficult-to-treat-resistant-pseudomonas-aeruginosa</guid><description>&lt;![CDATA[Because multiple overlapping mechanisms drive resistance in Pseudomonas aeruginosa, clinicians must test every relevant novel agent, with ceftolozane-tazobactam favored for difficult-to-treat resistant pneumonia.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:52:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Treating KPC and OXA-48-Like Carbapenemase Producers]]&gt;</title><link>https://www.contagionlive.com/view/treating-kpc-and-oxa-48-like-carbapenemase-producers</link><guid isPermaLink="true">https://www.contagionlive.com/view/treating-kpc-and-oxa-48-like-carbapenemase-producers</guid><description>&lt;![CDATA[Ceftazidime-avibactam and meropenem-vaborbactam remain reliable options for KPC producers, ceftazidime-avibactam is favored for OXA-48-like enzymes, and the US withdrawal of imipenem-relebactam narrows the available choices.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:51:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Cefepime-Zidebactam, a Novel Option for AMR Infections]]&gt;</title><link>https://www.contagionlive.com/view/cefepime-zidebactam-a-novel-option-for-amr-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/cefepime-zidebactam-a-novel-option-for-amr-infections</guid><description>&lt;![CDATA[Cefepime-zidebactam pairs a familiar cephalosporin with a beta-lactam enhancer that targets a second penicillin-binding protein, producing encouraging preclinical activity against carbapenem-resistant organisms ahead of clinical availability.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:50:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[NDM E. coli Cross-Resistance and Tetracyclines in AMR Infections]]&gt;</title><link>https://www.contagionlive.com/view/ndm-e-coli-cross-resistance-and-tetracyclines-in-amr-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/ndm-e-coli-cross-resistance-and-tetracyclines-in-amr-infections</guid><description>&lt;![CDATA[Penicillin-binding protein 3 alterations in NDM-producing E. coli can compromise both aztreonam-avibactam and cefiderocol simultaneously, while tetracycline derivatives retain a narrow role in carefully selected scenarios.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:49:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Dosing Novel AMR Agents During Renal Replacement Therapy]]&gt;</title><link>https://www.contagionlive.com/view/dosing-novel-amr-agents-during-renal-replacement-therapy</link><guid isPermaLink="true">https://www.contagionlive.com/view/dosing-novel-amr-agents-during-renal-replacement-therapy</guid><description>&lt;![CDATA[In critically ill patients receiving continuous renal replacement therapy, aggressive early dosing guided by effluent rate and close pharmacist partnership helps protect drug exposure when MICs already approach the breakpoint.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:48:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Reassessing Cefiderocol for NDM-Producing AMR Infections]]&gt;</title><link>https://www.contagionlive.com/view/reassessing-cefiderocol-for-ndm-producing-amr-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/reassessing-cefiderocol-for-ndm-producing-amr-infections</guid><description>&lt;![CDATA[Elevated MICs, NDM-mediated hydrolysis, and a concerning clinical mortality signal have prompted experts to question whether cefiderocol warrants equal standing with aztreonam-avibactam for NDM-producing Enterobacterales.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:47:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Aztreonam-Avibactam for AMR NDM-Producing Enterobacterales]]&gt;</title><link>https://www.contagionlive.com/view/aztreonam-avibactam-for-amr-ndm-producing-enterobacterales</link><guid isPermaLink="true">https://www.contagionlive.com/view/aztreonam-avibactam-for-amr-ndm-producing-enterobacterales</guid><description>&lt;![CDATA[Aztreonam-avibactam pairs a monobactam spared by NDM with an inhibitor of its companion enzymes, offering optimized pharmacodynamics and simpler administration, though NDM-specific clinical data remain limited.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:46:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Why NDM Carbapenemases Are Spreading in AMR Gram-Negative Infections]]&gt;</title><link>https://www.contagionlive.com/view/why-ndm-carbapenemases-are-spreading-in-amr-gram-negative-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/why-ndm-carbapenemases-are-spreading-in-amr-gram-negative-infections</guid><description>&lt;![CDATA[NDM has diversified and disseminated faster than any prior carbapenemase through mobile genetic elements and distinctive enzyme properties, yet KPC persists, requiring clinicians to account for both in therapeutic planning.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:45:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Rapid Diagnostics for AMR Gram-Negative Bloodstream Infections]]&gt;</title><link>https://www.contagionlive.com/view/rapid-diagnostics-for-amr-gram-negative-bloodstream-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/rapid-diagnostics-for-amr-gram-negative-bloodstream-infections</guid><description>&lt;![CDATA[Rapid molecular testing from positive blood cultures delivers actionable resistance data within hours, and knowing when each result arrives, and which are suppressed, shortens the time to effective therapy.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:44:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Empiric Risk Assessment and Carbapenemase Classification in AMR Infections]]&gt;</title><link>https://www.contagionlive.com/view/empiric-risk-assessment-and-carbapenemase-classification-in-amr-infections</link><guid isPermaLink="true">https://www.contagionlive.com/view/empiric-risk-assessment-and-carbapenemase-classification-in-amr-infections</guid><description>&lt;![CDATA[Empiric use of novel agents should follow patient-level risk and unit-level epidemiology, while a shared vocabulary for carbapenem-resistant Enterobacterales and their carbapenemases underpins every subsequent treatment decision.]]&gt;</description><pubDate>Fri, 13 Nov 2026 20:43:40 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Measles Update: November 13, 2026]]&gt;</title><link>https://www.contagionlive.com/view/measles-update-november-13-2026</link><guid isPermaLink="true">https://www.contagionlive.com/view/measles-update-november-13-2026</guid><description>&lt;![CDATA[The latest CDC numbers show a 4.4% increase of measles cases from week-to-week. Hospitalizations have reached 591, or 11% of all 2026 cases, and the Pan American Health Organization is deciding this week whether the United States has lost its measles elimination status.
]]&gt;</description><pubDate>Fri, 13 Nov 2026 16:21:12 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[FAQ: XDR Shigella]]&gt;</title><link>https://www.contagionlive.com/view/faq-xdr-shigella</link><guid isPermaLink="true">https://www.contagionlive.com/view/faq-xdr-shigella</guid><description>&lt;![CDATA[Here is some important information around this pathogen and the intestinal infection. ]]&gt;</description><pubDate>Fri, 13 Nov 2026 13:41:18 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[Shifting AMR Gram-Negative Resistance Trends in the US]]&gt;</title><link>https://www.contagionlive.com/view/shifting-amr-gram-negative-resistance-trends-in-the-us</link><guid isPermaLink="true">https://www.contagionlive.com/view/shifting-amr-gram-negative-resistance-trends-in-the-us</guid><description>&lt;![CDATA[Overall gram-negative resistance rates have plateaued, but the carbapenemases driving carbapenem resistance have shifted, with NDM expanding alongside KPC and reshaping treatment considerations across the Enterobacterales.]]&gt;</description><pubDate>Fri, 13 Nov 2026 08:40:00 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[The Prospective Emergence of XDR Shigella Beyond High-Risk Groups]]&gt;</title><link>https://www.contagionlive.com/view/the-prospective-emergence-of-xdr-shigella-beyond-high-risk-groups</link><guid isPermaLink="true">https://www.contagionlive.com/view/the-prospective-emergence-of-xdr-shigella-beyond-high-risk-groups</guid><description>&lt;![CDATA[Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team&apos;s work in this area and the role of genomic sequencing to uncover this troublesome pathogen. ]]&gt;</description><pubDate>Thu, 12 Nov 2026 18:31:35 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[CDC Investigators of Enteric Fever Favor Tailored Treatment ]]&gt;</title><link>https://www.contagionlive.com/view/cdc-investigators-of-enteric-fever-favor-tailored-treatment</link><guid isPermaLink="true">https://www.contagionlive.com/view/cdc-investigators-of-enteric-fever-favor-tailored-treatment</guid><description>&lt;![CDATA[Enteric fever (typhoid or paratyphoid fever) infection in travelers returning to the US is likely resistant to ciprofloxacin, and with some cases also resistant to ceftriaxone, CDC investigators advise treatment guided by susceptibility.]]&gt;</description><pubDate>Thu, 12 Nov 2026 15:07:59 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item><item><title>&lt;![CDATA[CDC Updates Report on Antimicrobial Resistance ]]&gt;</title><link>https://www.contagionlive.com/view/cdc-updates-report-on-antimicrobial-resistance</link><guid isPermaLink="true">https://www.contagionlive.com/view/cdc-updates-report-on-antimicrobial-resistance</guid><description>&lt;![CDATA[The 2026 Antimicrobial Resistance Threats Report from the CDC categorizes 19 bacterial and fungal pathogens by level of threat to health in the US.]]&gt;</description><pubDate>Wed, 11 Nov 2026 16:12:56 GMT</pubDate><media:credit role="publishing company">Contagion Live</media:credit><category>us</category><source url="https://www.contagionlive.com/rss.xml">Contagion Live Articles</source></item></channel></rss>